Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $78.5M
- Insider buysLast 90 days, $1.00M in total
- 1
- Insider sellsLast 90 days, $40.9K in total
- 1
- 13F holdersQ2 2026, +3 vs. previous quarter
- 36
- 13F valueReported value at the end of Q2 2026
- $51.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $120.8M
- −6.3% year over year
- Net income, FY2025
- $32.7M
- No comparable prior period
- Free cash flow, FY2025
- -$50.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $1.22M
- −64.6% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 296.7K
- Shares sold short
- Change
- −53.6K
- −15.3% vs. previous
- Days to cover
- 13.43
- At average daily volume
Superinvestors holding ATRA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ATRA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Atara Biotherapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 (view filing)6:20 PM ET | Sep 4 | Same day | Cherry Brian NDirector | PPurchase | +104.2K | $9.60 | +$1.00M | +167.1%166.5K after | |
| Aug 26, 2026 (view filing)7:45 PM ET | Aug 17 | 9 daysLate | Nguyen AnhCoPresident and CEO | SSale | −5.06K | $8.08 | −$40.9K | −3.7%132.8K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Nguyen AnhCoPresident and CEO | SSale | −5.24K | $9.13 | −$47.9K | −3.7%137.8K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Grant-Huerta YaninaChief Accounting Officer | SSale | −2.41K | $9.13 | −$22.0K | −4.6%49.6K after | |
| May 11, 2026 (view filing)6:45 PM ET | May 7 | 4 days | Huang James and 1 otherDirector, 10% Owner | SSale | −313.4K | $10.10 | −$3.17M | −23.7%1.01M after | |
| May 11, 2026 (view filing) | May 7 | 4 days | EcoR1 Capital, LLC10% Owner | PPurchase | +507.4K | $9.35 | +$4.74M | +48.6%1.55M after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Grant-Huerta YaninaChief Accounting Officer | SSale | −2.10K | $5.08 | −$10.7K | −6.2%31.8K after | 4 lots |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Nguyen AnhCoPresident and CEO | SSale | −3.00K | $5.09 | −$15.2K | −4.6%62.0K after | 4 lots |
| Jan 14, 2026 (view filing)9:16 PM ET | Jan 12 | 2 days | Huang James and 1 otherDirector, 10% Owner | SSale | −80.6K | $6.07 | −$489.0K | −5.7%1.32M after | |
| Nov 19, 2025 (view filing) | Nov 17 | 2 days | Nguyen AnhCoPresident and CEO | SSale | −2.92K | $13.19 | −$38.4K | −4.3%65.0K after | 2 lots |
Top 10 13F holders, Q2 2026
See all 36 holdersThe largest institutional positions in Atara Biotherapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 1,552,000 | $17.8M | 0.88% | +1,452,407+1,458.3% | Added |
| Adage Capital Partners GP, L.L.C. | 850,000 | $9.76M | 0.01% | +150,000+21.4% | Added |
| Point72 Asset Management, L.P. | 687,718 | $7.90M | 0.01% | +493,454+254.0% | Added |
| Redmile Group, LLC | 441,701 | $5.07M | 0.34% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 247,047 | $2.84M | 0.00% | +29,185+13.4% | Added |
| Mackenzie Financial Corp | 233,249 | $2.68M | 0.00% | −80,371−25.6% | Reduced |
| BlackRock, Inc. | 84,455 | $969.5K | 0.00% | +5,433+6.9% | Added |
| Geode Capital Management, LLC | 75,128 | $862.9K | 0.00% | +8,982+13.6% | Added |
| Staley Capital Advisers Inc | 50,000 | $574.0K | 0.02% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 43,036 | $494.1K | 0.00% | +9,415+28.0% | Added |
Holders of 5% or more of ATRA
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Atara Biotherapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Adiumentum Capital Fund I LP | 13D/A | 19.99%1.37M shares | – | May 22, 20243 filings | May 16, 2025 | SEC |
| EcoR1 Capital, LLC | 13G/A | 17.40%1.55M shares | +7.50 ppfrom 9.90% | Nov 21, 20234 filings | May 7, 2026 | SEC |
| Panacea Innovation Ltd | 13D/A | 16.10%1.32M shares | −3.89 ppfrom 19.99% | May 21, 20254 filings | May 11, 2026 | SEC |
| Redmile Group, LLC | 13D/A | 9.90%951.0K shares | 0.00 ppfrom 9.90% | Feb 16, 202110 filings | Jul 24, 2026 | SEC |
| Panacea Innovation Ltd | 13G | 9.50%550.0K shares | New | Feb 6, 20251 filing | Feb 6, 2025 | SEC |